Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature Case report
Article Sidebar
Published:
May 23, 2016
Keywords:
papillary renal cell carcinoma, molecular targeted therapies
Main Article Content
Abstract
Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted therapies, which are about the progress in clear cell carcinoma. We present an overview of the treatment trials and report a casuistic case of metastatic disease controlled for several years with pazopanib.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Buraczewska A, Kardas J. Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature. OncoReview [Internet]. 2016May23 [cited 2024May4];6(2(22):62-5. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/479
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Krzakowski M, Warzocha K. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych – 2013. Vol 1. Via Medica, Gdańsk 2013.
2. Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii49-56.
3. Senkus-Konefka E, Zdrojowy R. Nowotwory układu moczowo-płciowego. Praktyczny przewodnik dla lekarzy. Via Medica, Gdańsk 2013.
4. Barama A, St-Louis G, Nicolet V et al. Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant 2005; 5(12): 3015-3018.
5. Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia kliniczna. Vol 2. Via Medica, Gdańsk 2015.
6. Courthod G, Tucci M, DiMaio M. et al. Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev in Oncol/Hematol 2015; 96: 100-112.
7. Twardowski PW, Mack PC, Lara PN Jr. Papillary Renal Cell Carcinoma: Current Progress and Future Directions. Clin Genitourin Cancer 2014; 12(2): 74-79.
8. Linehan WM, Spellman PT, Ricketts CJ et al; Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016; 374(2): 135-145 [epub ahead of print].
9. Tannir NM, Jonasch E, Albiges L et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 2015 Nov 25.
10. Escudier B, Ravaud A, Negrier S et al. Update on AVOREN trial in metastatic renal cell carcinoma: efficacy and safety in subgroups of patients and pharmacokinetic analysis. J Clin Oncol 2008; 26(suppl. 15S) (abstract 5025).
11. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 758-763.
12. Plimack ER, Jonasch E, Bekele N et al. Sunitinib in non-clear cell renal cell carcinoma: a phase II study. J Clin Oncol 2008; 26(suppl) (abstract 5112).
13. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in etastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
14. Stadler W, Figlin R, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-1280.
15. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
16. Escudier B, Bracarda S, Maroto JP et al. Open-label phase II trial of first-line everolimus monotherapy in patients with advanced papillary renal cell carcinoma. RAPTOR final analysis. European Cancer Congress 2013: abstract 2706.
17. Bellon SF, Kaplan-Lefko P, Yang Y. et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008; 283: 2676-2683.
18. Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31: 181-186.
19. Gordon MS, Hussey M, Nagle RB et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009; 27: 5788-5793.
20. Choueiri TK, Fay AP, Gray KP et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014; 25(11): 2178-2184.
2. Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii49-56.
3. Senkus-Konefka E, Zdrojowy R. Nowotwory układu moczowo-płciowego. Praktyczny przewodnik dla lekarzy. Via Medica, Gdańsk 2013.
4. Barama A, St-Louis G, Nicolet V et al. Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant 2005; 5(12): 3015-3018.
5. Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia kliniczna. Vol 2. Via Medica, Gdańsk 2015.
6. Courthod G, Tucci M, DiMaio M. et al. Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev in Oncol/Hematol 2015; 96: 100-112.
7. Twardowski PW, Mack PC, Lara PN Jr. Papillary Renal Cell Carcinoma: Current Progress and Future Directions. Clin Genitourin Cancer 2014; 12(2): 74-79.
8. Linehan WM, Spellman PT, Ricketts CJ et al; Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016; 374(2): 135-145 [epub ahead of print].
9. Tannir NM, Jonasch E, Albiges L et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 2015 Nov 25.
10. Escudier B, Ravaud A, Negrier S et al. Update on AVOREN trial in metastatic renal cell carcinoma: efficacy and safety in subgroups of patients and pharmacokinetic analysis. J Clin Oncol 2008; 26(suppl. 15S) (abstract 5025).
11. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 758-763.
12. Plimack ER, Jonasch E, Bekele N et al. Sunitinib in non-clear cell renal cell carcinoma: a phase II study. J Clin Oncol 2008; 26(suppl) (abstract 5112).
13. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in etastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
14. Stadler W, Figlin R, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-1280.
15. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
16. Escudier B, Bracarda S, Maroto JP et al. Open-label phase II trial of first-line everolimus monotherapy in patients with advanced papillary renal cell carcinoma. RAPTOR final analysis. European Cancer Congress 2013: abstract 2706.
17. Bellon SF, Kaplan-Lefko P, Yang Y. et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008; 283: 2676-2683.
18. Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31: 181-186.
19. Gordon MS, Hussey M, Nagle RB et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009; 27: 5788-5793.
20. Choueiri TK, Fay AP, Gray KP et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014; 25(11): 2178-2184.